Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
about
Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signalingSialic acids and autoimmune disease.Modulating carbohydrate-protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology.DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.
P2860
Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Extensive crosslinking of CD22 ...... tosis in human lymphoma cells.
@en
type
label
Extensive crosslinking of CD22 ...... tosis in human lymphoma cells.
@en
prefLabel
Extensive crosslinking of CD22 ...... tosis in human lymphoma cells.
@en
P2093
P2860
P1476
Extensive crosslinking of CD22 ...... tosis in human lymphoma cells.
@en
P2093
Chien-Hsing Chang
David M Goldenberg
Pankaj Gupta
P2860
P304
P356
10.4161/19420862.2014.979081
P577
2015-01-01T00:00:00Z